Stryker Corporation

Valuation Analysis

About the Company

Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and

Stryker Corporation Stock at a Glance

Stryker Corporation (SYK) is currently trading at $312.20 with a market capitalization of $119.7B. The trailing P/E ratio stands at 36.09x, with a forward P/E of 18.67x. The 52-week range spans from $281.00 to $404.87; the current price is 22.9% below the yearly high. Year-over-year revenue growth stands at +2.6%. The net profit margin stands at 13.21%.

💰 Dividend

Stryker Corporation pays an annual dividend of $3.52 per share, representing a yield of 1.13%. The payout ratio stands at 39.81%.

📊 Analyst Rating

25 analysts rate Stryker Corporation (SYK) on consensus: Buy. The average price target is $386.80, implying +23.89% from the current price. Analyst price targets range from $315.00 to $465.00.

Stryker Corporation: The Investment Case in Detail

Stryker Corporation (SYK) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

With a gross margin near 64.7%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Buy with an average price target implying roughly 23.89% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue growth has slowed to just 2.6%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

The PEG ratio at 1.49 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 18.67x is meaningfully below the trailing 36.09x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 23.89% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Stryker Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.